📰 Adara Wright News
Page 2 - Adara Wright News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Adara Wright. Real-time updates on events, politics, business and more.
January 22, 2024
Advisor OS LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 6.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,020 shares of the medical research company’s stock after acquiring an additional […]
January 16, 2024
Dara Wright Joins Madison Industries to Lead Madison Medical
January 8, 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been assigned a consensus recommendation of “Buy” from the four research firms that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock […]
May 5, 2023
Operator: Good afternoon. Thank you for attending the Bio-Rad First Quarter 2023 Earnings Conference Call. My name is Matt, and Ill be your moderator for todays call.
February 20, 2023
Operator: Good afternoon, ladies and gentlemen. Thank you for attending todays Bio-Rad Fourth Quarter and Full Year 2022 Earnings Results Conference Call.
October 6, 2022
Because this section is free of charge, community events are subject to run based on available space. Email events to calendar@newsadvance.com.
August 4, 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WS...
August 4, 2022
Bio-Rad will gain Curiosity Diagnostics' PCR|One platform, a sample-to-answer, rapid diagnostics PCR system under development.
August 3, 2022
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding
February 28, 2022
With new focus, the firm expects to grow its compound annual growth rate from 5.2 percent to 9 percent over the next few years.